Nutriband Nears Profitability With Ambitious Growth Targets Nutriband Inc., a developer of transdermal pharmaceutical products, is projected to achieve profitability by 2027. Analysts anticipate an 85% annual growth rate to meet this goal. Despite recent losses, the company maintains a strong equity-funded structure with minimal debt, which positions it well for its ambitious growth trajectory.1